LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 14

Search options

  1. Article ; Online: Zika Virus Induces Mitotic Catastrophe in Human Neural Progenitors by Triggering Unscheduled Mitotic Entry in the Presence of DNA Damage While Functionally Depleting Nuclear PNKP.

    Rychlowska, Malgorzata / Agyapong, Abigail / Weinfeld, Michael / Schang, Luis M

    Journal of virology

    2022  Volume 96, Issue 9, Page(s) e0033322

    Abstract: Vertical transmission of Zika virus (ZIKV) leads with high frequency to congenital ZIKV syndrome (CZS), whose worst outcome is microcephaly. However, the mechanisms of congenital ZIKV neurodevelopmental pathologies, including direct cytotoxicity to ... ...

    Abstract Vertical transmission of Zika virus (ZIKV) leads with high frequency to congenital ZIKV syndrome (CZS), whose worst outcome is microcephaly. However, the mechanisms of congenital ZIKV neurodevelopmental pathologies, including direct cytotoxicity to neural progenitor cells (NPC), placental insufficiency, and immune responses, remain incompletely understood. At the cellular level, microcephaly typically results from death or insufficient proliferation of NPC or cortical neurons. NPC replicate fast, requiring efficient DNA damage responses to ensure genome stability. Like congenital ZIKV infection, mutations in the polynucleotide 5'-kinase 3'-phosphatase (PNKP) gene, which encodes a critical DNA damage repair enzyme, result in recessive syndromes often characterized by congenital microcephaly with seizures (MCSZ). We thus tested whether there were any links between ZIKV and PNKP. Here, we show that two PNKP phosphatase inhibitors or PNKP knockout inhibited ZIKV replication. PNKP relocalized from the nucleus to the cytoplasm in infected cells, colocalizing with the marker of ZIKV replication factories (RF) NS1 and resulting in functional nuclear PNKP depletion. Although infected NPC accumulated DNA damage, they failed to activate the DNA damage checkpoint kinases Chk1 and Chk2. ZIKV also induced activation of cytoplasmic CycA/CDK1 complexes, which trigger unscheduled mitotic entry. Inhibition of CDK1 activity inhibited ZIKV replication and the formation of RF, supporting a role of cytoplasmic CycA/CDK1 in RF morphogenesis. In brief, ZIKV infection induces mitotic catastrophe resulting from unscheduled mitotic entry in the presence of DNA damage. PNKP and CycA/CDK1 are thus host factors participating in ZIKV replication in NPC, and pathogenesis to neural progenitor cells.
    MeSH term(s) DNA Damage ; DNA Repair Enzymes/genetics ; Humans ; Microcephaly/virology ; Mitosis ; Neural Stem Cells/cytology ; Neural Stem Cells/virology ; Phosphotransferases (Alcohol Group Acceptor)/genetics ; Zika Virus ; Zika Virus Infection/pathology
    Chemical Substances PNKP protein, human (EC 2.7.1.-) ; Phosphotransferases (Alcohol Group Acceptor) (EC 2.7.1.-) ; DNA Repair Enzymes (EC 6.5.1.-)
    Language English
    Publishing date 2022-04-12
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80174-4
    ISSN 1098-5514 ; 0022-538X
    ISSN (online) 1098-5514
    ISSN 0022-538X
    DOI 10.1128/jvi.00333-22
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Recombinant Flag-tagged E1E2 glycoproteins from three hepatitis C virus genotypes are biologically functional and elicit cross-reactive neutralizing antibodies in mice.

    Krapchev, Vasil B / Rychłowska, Malgorzata / Chmielewska, Alicja / Zimmer, Karolina / Patel, Arvind H / Bieńkowska-Szewczyk, Krystyna

    Virology

    2018  Volume 519, Page(s) 33–41

    Abstract: Hepatitis C virus (HCV) is a globally disseminated human pathogen for which no vaccine is currently available. HCV is highly diverse genetically and can be classified into 7 genotypes and multiple sub-types. Due to this antigenic variation, the induction ...

    Abstract Hepatitis C virus (HCV) is a globally disseminated human pathogen for which no vaccine is currently available. HCV is highly diverse genetically and can be classified into 7 genotypes and multiple sub-types. Due to this antigenic variation, the induction of cross-reactive and at the same time neutralizing antibodies is a challenge in vaccine production. Here we report the analysis of immunogenicity of recombinant HCV envelope glycoproteins from genotypes 1a, 1b and 2a, with a Flag tag inserted in the hypervariable region 1 of E2. This modification did not affect protein expression or conformation or its capacity to bind the crucial virus entry factor, CD81. Importantly, in immunogenicity studies on mice, the purified E2-Flag mutants elicited high-titer, cross-reactive antibodies that were able to neutralize HCV infectious particles from two genotypes tested (1a and 2a). These findings indicate that E1E2-Flag envelope glycoproteins could be important immunogen candidates for vaccine aiming to induce broad HCV-neutralizing responses.
    MeSH term(s) Animals ; Antibodies, Neutralizing/biosynthesis ; Antibodies, Neutralizing/immunology ; Antibodies, Viral/immunology ; Cell Line ; Cross Reactions ; Epitope Mapping ; Epitopes/immunology ; Genotype ; Hepacivirus/genetics ; Hepacivirus/immunology ; Hepacivirus/physiology ; Humans ; Immunogenicity, Vaccine ; Mice ; Neutralization Tests ; Receptors, Virus/metabolism ; Recombinant Proteins/chemistry ; Recombinant Proteins/immunology ; Tetraspanin 28/metabolism ; Viral Envelope Proteins/chemistry ; Viral Envelope Proteins/genetics ; Viral Envelope Proteins/immunology ; Viral Envelope Proteins/metabolism ; Virus Internalization
    Chemical Substances Antibodies, Neutralizing ; Antibodies, Viral ; E1 protein, Hepatitis C virus ; Epitopes ; Receptors, Virus ; Recombinant Proteins ; Tetraspanin 28 ; Viral Envelope Proteins ; glycoprotein E2, Hepatitis C virus (157184-61-7)
    Language English
    Publishing date 2018-04-06
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 200425-2
    ISSN 1096-0341 ; 0042-6822
    ISSN (online) 1096-0341
    ISSN 0042-6822
    DOI 10.1016/j.virol.2018.03.026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Antivirals--current trends in fighting influenza.

    Król, Ewelina / Rychłowska, Małgorzata / Szewczyk, Bogusław

    Acta biochimica Polonica

    2014  Volume 61, Issue 3, Page(s) 495–504

    Abstract: Influenza virus infection is a major source of morbidity and mortality worldwide. Due to the variable effectiveness of existing vaccines, especially in the early stages of an epidemic, antiviral drugs represent the first line of defense against the virus. ...

    Abstract Influenza virus infection is a major source of morbidity and mortality worldwide. Due to the variable effectiveness of existing vaccines, especially in the early stages of an epidemic, antiviral drugs represent the first line of defense against the virus. Currently, there are two major classes of anti-influenza drugs approved by the FDA for clinical use: M2 protein inhibitors (amantadine and rimantadine) and neuraminidase inhibitors (zanamivir and oseltamivir). However, increasing resistance to these available influenza antivirals among circulating influenza viruses highlights the need to develop alternative approaches for the prevention and/or treatment of influenza. This review presents an overview of currently available drugs for influenza treatment as well as summarizes some new antiviral strategies that are now being tested covering agents targeting both the viral proteins and the host-virus interaction. We discuss their mechanisms of action, resistance and the therapeutic potential as new antiviral drug for use in future influenza pandemics. Additionally, combination therapy based on these drugs is also described.
    MeSH term(s) Amantadine/therapeutic use ; Antiviral Agents/therapeutic use ; Disease Outbreaks/prevention & control ; Drug Therapy, Combination/trends ; Enzyme Inhibitors/therapeutic use ; Humans ; Influenza A virus/drug effects ; Influenza, Human/drug therapy ; Influenza, Human/epidemiology ; Neuraminidase/antagonists & inhibitors ; Oseltamivir/therapeutic use ; Rimantadine/therapeutic use ; Viral Matrix Proteins/antagonists & inhibitors ; Zanamivir/therapeutic use
    Chemical Substances Antiviral Agents ; Enzyme Inhibitors ; M2 protein, Influenza A virus ; Viral Matrix Proteins ; Rimantadine (0T2EF4JQTU) ; Oseltamivir (20O93L6F9H) ; Amantadine (BF4C9Z1J53) ; Neuraminidase (EC 3.2.1.18) ; Zanamivir (L6O3XI777I)
    Language English
    Publishing date 2014
    Publishing country Poland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 595762-x
    ISSN 1734-154X ; 0001-527X
    ISSN (online) 1734-154X
    ISSN 0001-527X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Hepatitis C--new developments in the studies of the viral life cycle.

    Rychłowska, Małgorzata / Bieńkowska-Szewczyk, Krystyna

    Acta biochimica Polonica

    2007  Volume 54, Issue 4, Page(s) 703–715

    Abstract: Hepatitis C virus (HCV) is a causative agent of chronic liver disease leading to cirrhosis, liver failure and hepatocellular carcinoma. The prevalence of HCV is estimated as 3% of the world population and the virus is a major public health problem all ... ...

    Abstract Hepatitis C virus (HCV) is a causative agent of chronic liver disease leading to cirrhosis, liver failure and hepatocellular carcinoma. The prevalence of HCV is estimated as 3% of the world population and the virus is a major public health problem all over the world. For over 16 years, since HCV had been discovered, studies of the mechanisms of the viral life cycle and virus-host interactions have been hampered by the lack of a cell culture system allowing the virus to be grown in laboratory conditions. However, in recent years some new model systems to study HCV have been developed. The major breakthrough of the last two years was the cell culture system for maintaining the virus in an adapted hepatocyte-derived cell line. This review describes the techniques and applications of most of the in vitro systems and animal models currently used for working with hepatitis C virus.
    MeSH term(s) Animals ; Hepacivirus/growth & development ; Humans ; Life Cycle Stages
    Language English
    Publishing date 2007
    Publishing country Poland
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 595762-x
    ISSN 1734-154X ; 0001-527X
    ISSN (online) 1734-154X
    ISSN 0001-527X
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Wirusowe zapalenie wątroby typu C-nowe metody leczenia i zapobiegania.

    Chmielewska, Alicja M / Rychłowska, Małgorzata / Król, Ewelina / Solarz, Karolina / Bieńkowska-Szewczyk, Krystyna

    Postepy higieny i medycyny doswiadczalnej (Online)

    2015  Volume 69, Page(s) 946–963

    Abstract: Despite available treatment, Hepatitis C remains one of most serious burdens to public health. Current therapy based on pegylated interferon-alpha and ribavirin has significant side effects and its effectiveness varies for different genotypes of the ... ...

    Title translation Novel methods of hepatitis C treatment and prevention.
    Abstract Despite available treatment, Hepatitis C remains one of most serious burdens to public health. Current therapy based on pegylated interferon-alpha and ribavirin has significant side effects and its effectiveness varies for different genotypes of the virus. Four novel drugs - viral protease inhibitors (telaprevir, boceprevir, simeprevir) and polymerase inhibitor - sofosbuvir have been introduced in last years for use in combination with standard-of-care treatment. For the first time interferon free therapies were approved with the use of combination of sofosbuvir+ribavirin. New therapies improve virological response rates but also increase the cost, side effects and raise the issue of drug resistance. Numerous novel anti-HCV compounds have been evaluated in advanced clinical trials including inhibitors of viral proteins (protease, polymerase and NS5A) and inhibitors of host factors involved in HCV replication (cyclophilin A, microRNA - miR-122). New interferon-free therapies reducing severe side effects are expected to enter the market within few months. At the same time efforts are undertaken to determine the host and viral factors with predictive value for HCV treatment response, enabling personalized therapy approach. The main success in this field was the discovery of interleukin IL28B polymorphism, which correlates with positive standard-of-care treatment response. An effective vaccination may be an alternative for antiviral drugs, but no anti-HCV vaccine is available currently. It is well proved that successful vaccination should induce antibody and T-cell responses specific against a range of HCV genotypes. With this aim, new subunit and genetic candidate vaccines have been evaluated in I and II phase clinical trials. This review summarizes the recent developments in the field of new drug development and vaccine studies against hepatitis C virus.
    MeSH term(s) Antiviral Agents/therapeutic use ; Hepacivirus/drug effects ; Hepatitis C/diagnosis ; Hepatitis C/drug therapy ; Hepatitis C/prevention & control ; Humans ; Oligopeptides/therapeutic use ; Protease Inhibitors/therapeutic use ; Ribavirin/therapeutic use ; Simeprevir/therapeutic use
    Chemical Substances Antiviral Agents ; Oligopeptides ; Protease Inhibitors ; Ribavirin (49717AWG6K) ; telaprevir (655M5O3W0U) ; Simeprevir (9WS5RD66HZ)
    Language Polish
    Publishing date 2015-08-19
    Publishing country Poland
    Document type English Abstract ; Journal Article ; Review
    ZDB-ID 418865-2
    ISSN 1732-2693 ; 0032-5449
    ISSN (online) 1732-2693
    ISSN 0032-5449
    DOI 10.5604/17322693.1165197
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Novel methods of hepatitis C treatment and prevention

    Alicja M. Chmielewska / Małgorzata Rychłowska / Ewelina Król / Karolina Solarz / Krystyna Bieńkowska-Szewczyk

    Postępy Higieny i Medycyny Doświadczalnej, Vol 69, Pp 946-

    2015  Volume 963

    Abstract: Despite available treatment, Hepatitis C remains one of most serious burdens to public health. Current therapy based on pegylated interferon-alpha and ribavirin has significant side effects and its effectiveness varies for different genotypes of the ... ...

    Abstract Despite available treatment, Hepatitis C remains one of most serious burdens to public health. Current therapy based on pegylated interferon-alpha and ribavirin has significant side effects and its effectiveness varies for different genotypes of the virus. Four novel drugs – viral protease inhibitors (telaprevir, boceprevir, simeprevir) and polymerase inhibitor – sofosbuvir have been introduced in last years for use in combination with standard-of-care treatment. For the first time interferon free therapies were approved with the use of combination of sofosbuvir+ribavirin. New therapies improve virological response rates but also increase the cost, side effects and raise the issue of drug resistance. Numerous novel anti-HCV compounds have been evaluated in advanced clinical trials including inhibitors of viral proteins (protease, polymerase and NS5A) and inhibitors of host factors involved in HCV replication (cyclophilin A, microRNA – miR-122). New interferon-free therapies reducing severe side effects are expected to enter the market within few months. At the same time efforts are undertaken to determine the host and viral factors with predictive value for HCV treatment response, enabling personalized therapy approach. The main success in this field was the discovery of interleukin IL28B polymorphism, which correlates with positive standard-of-care treatment response. An effective vaccination may be an alternative for antiviral drugs, but no anti-HCV vaccine is available currently. It is well proved that successful vaccination should induce antibody and T-cell responses specific against a range of HCV genotypes. With this aim, new subunit and genetic candidate vaccines have been evaluated in I and II phase clinical trials. This review summarizes the recent developments in the field of new drug development and vaccine studies against hepatitis C virus.
    Keywords hepatitis C virus ; Antivirals ; antiviral therapy ; Viral Vaccines ; wirus zapalenia wątroby typu C ; leki przeciwwirusowe ; Medicine ; R
    Subject code 610
    Language English
    Publishing date 2015-08-01T00:00:00Z
    Publisher Sciendo
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  7. Article ; Online: Application of baculovirus-insect cell expression system for human therapy.

    Rychlowska, Malgorzata / Gromadzka, Beata / Bieńkowska-Szewczyk, Krystyna / Szewczyk, Boguslaw

    Current pharmaceutical biotechnology

    2011  Volume 12, Issue 11, Page(s) 1840–1849

    Abstract: A major advantage of recombinant DNA technology is its flexibility allowing for "on demand" production of specific proteins with theurapeutic value in heterologous expression systems. Gene expression vectors based on baculovirus, insect virus attacking ... ...

    Abstract A major advantage of recombinant DNA technology is its flexibility allowing for "on demand" production of specific proteins with theurapeutic value in heterologous expression systems. Gene expression vectors based on baculovirus, insect virus attacking mostly lepidopteran species, are frequently used for relatively inexpensive and fast production of such proteins. This expression system is recognized as one of the most powerful technologies for commercial synthesis of glycoproteins originating from vertebrate themselves or from vertebrate viruses. Glycosylation pathways utilized by insects are not identical, though they are similar to vertebrate glycosylation pathways. In the review special attention is given to the development of new virus-like particles (VLPs) potential vaccines which represent a novel class of subunit vaccines that are able to stimulate efficiently cellular and humoral immune responses against viral agents. Apart from production of vertebrate proteins or VLPs "on demand " in insect cells, a new exciting field of using baculovirus as gene delivery system to vertebrate cells was recently open which has a great potential for future uses of baculovirus as effective gene therapy vector.
    MeSH term(s) Animals ; Baculoviridae/genetics ; Baculoviridae/growth & development ; Baculoviridae/immunology ; Gene Transfer Techniques ; Genetic Engineering/methods ; Genetic Engineering/trends ; Genetic Vectors ; Humans ; Lepidoptera/genetics ; Lepidoptera/virology ; Technology, Pharmaceutical/methods ; Technology, Pharmaceutical/trends ; Transfection ; Vaccines, Virus-Like Particle/chemistry ; Vaccines, Virus-Like Particle/genetics ; Vaccines, Virus-Like Particle/therapeutic use ; Virus Diseases/immunology ; Virus Diseases/prevention & control
    Chemical Substances Vaccines, Virus-Like Particle
    Language English
    Publishing date 2011-09-07
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2132197-8
    ISSN 1873-4316 ; 1389-2010
    ISSN (online) 1873-4316
    ISSN 1389-2010
    DOI 10.2174/138920111798377012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Tumor expression of survivin, p53, cyclin D1, osteopontin and fibronectin in predicting the response to neo-adjuvant chemotherapy in children with advanced malignant peripheral nerve sheath tumor.

    Karpinsky, Gabrielle / Krawczyk, Malgorzata A / Izycka-Swieszewska, Ewa / Fatyga, Aleksandra / Budka, Agnieszka / Balwierz, Walentyna / Sobol, Grazyna / Zalewska-Szewczyk, Beata / Rychlowska-Pruszynska, Magdalena / Klepacka, Teresa / Dembowska-Baginska, Bozenna / Kazanowska, Bernarda / Gabrych, Anna / Bien, Ewa

    Journal of cancer research and clinical oncology

    2018  Volume 144, Issue 3, Page(s) 519–529

    Abstract: Purpose: Selected cell-cycle regulators and extracellular matrix proteins were found to play roles in malignant peripheral nerve sheath tumor (MPNST) biology. We aimed to analyze whether initial tumor tissue expressions of survivin, p53, cyclin D1, ... ...

    Abstract Purpose: Selected cell-cycle regulators and extracellular matrix proteins were found to play roles in malignant peripheral nerve sheath tumor (MPNST) biology. We aimed to analyze whether initial tumor tissue expressions of survivin, p53, cyclin D1, osteopontin (OPN) and fibronectin (FN) correlate with the response to neo-adjuvant CHT (naCHT) in children with advanced inoperable MPNST.
    Methods: The study included 26 children with MPNST (M/F 14/12, median age 130 months) treated in Polish centers of pediatric oncology between 1992 and 2013. Tissue expression of markers was studied immunohistochemically in the manually performed tissue microarrays and assessed semi-quantitatively as low and high, based on the rate of positive cells and staining intensity.
    Results: Good response to naCHT was noted in 47.6%, while poor-in 52.4% of patients. The response to naCHT was influenced negatively by the presence of neurofibromatosis NF1 and high initial tumor tissue expression of OPN, survivin, p53 and cyclin D1. Patients with high tumor expression of either OPN, survivin or p53 and those with simultaneous high expression of ≥ 3 of the markers, responded significantly worse to naCHT, than patients, in whom expression of ≤ 2 markers were detected at diagnosis. Nearly, 85% of patients expressing ≥ 3 markers, responded poor to CHT; while 87.5% of children, expressing ≤ 2 markers, were good responders.
    Conclusion: The initial tumor tissue expression of OPN, survivin, p53 and cyclin D1 may serve as markers to predict response to naCHT in pediatric advanced MPNST. Future studies in more numerous group of patients are needed to confirm these preliminary results.
    MeSH term(s) Adolescent ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Pharmacological/metabolism ; Biomarkers, Tumor/metabolism ; Child ; Child, Preschool ; Cyclin D1/metabolism ; Cytokines/metabolism ; Disease Progression ; Female ; Humans ; Infant ; Inhibitor of Apoptosis Proteins/metabolism ; Male ; Neoadjuvant Therapy ; Nerve Sheath Neoplasms/diagnosis ; Nerve Sheath Neoplasms/drug therapy ; Nerve Sheath Neoplasms/metabolism ; Nerve Sheath Neoplasms/pathology ; Neurilemmoma/drug therapy ; Neurilemmoma/metabolism ; Neurilemmoma/pathology ; Osteopontin/metabolism ; Prognosis ; Treatment Outcome
    Chemical Substances BIRC5 protein, human ; Biomarkers, Pharmacological ; Biomarkers, Tumor ; CCND1 protein, human ; Cytokines ; FN1 protein, human ; Inhibitor of Apoptosis Proteins ; SPP1 protein, human ; Osteopontin (106441-73-0) ; Cyclin D1 (136601-57-5)
    Language English
    Publishing date 2018-03
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 134792-5
    ISSN 1432-1335 ; 0171-5216 ; 0084-5353 ; 0943-9382
    ISSN (online) 1432-1335
    ISSN 0171-5216 ; 0084-5353 ; 0943-9382
    DOI 10.1007/s00432-018-2580-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Anti-influenza A virus activity of uridine derivatives of 2-deoxy sugars.

    Krol, Ewelina / Wandzik, Ilona / Gromadzka, Beata / Nidzworski, Dawid / Rychlowska, Malgorzata / Matlacz, Marta / Tyborowska, Jolanta / Szewczyk, Boguslaw

    Antiviral research

    2013  Volume 100, Issue 1, Page(s) 90–97

    Abstract: Influenza viruses are important pathogens that cause respiratory infections in humans and animals. Apart from vaccinations, antiviral drugs play a significant role in controlling spread of the disease. Influenza A virus contains two membrane ... ...

    Abstract Influenza viruses are important pathogens that cause respiratory infections in humans and animals. Apart from vaccinations, antiviral drugs play a significant role in controlling spread of the disease. Influenza A virus contains two membrane glycoproteins on the external part of viral envelope: hemagglutinin (HA) and neuraminidase (NA), which are crucial for productive infection in target cells. In the present work, two derivatives of tunicamycin - uridine derivatives of 2-deoxy sugars (designated IW3 and IW7), which target the glycan processing steps during maturation of viral glycoproteins, were assayed for their ability to inhibit influenza A virus infection in vitro. Using the cytopathic effect (CPE) inhibition assay and viral plaque reduction assay we showed, that both IW3 and IW7 inhibitors exerted significant inhibitory effect on influenza A virus infection in MDCK cells without significant toxicity for the cells. Moreover, tested compounds selectively suppressed viral protein expression in a dose-dependent manner, suggesting that the mechanism of their antiviral activity may be similar to this shown previously for other viruses. We have also excluded the possibility that both inhibitors act at the replication step of virus life cycle. Using real-time PCR assay it was shown that IW3 and IW7 did not change the level of viral RNA in infected MDCK cells after a single round of infection. Therefore, inhibition of influenza A virus infection by uridine derivatives of 2-deoxy sugars, acting as glycosylation inhibitors, is a promising alternative approach for the development of new anti-influenza A therapy.
    MeSH term(s) Animals ; Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; Cell Line ; Deoxy Sugars/chemistry ; Deoxy Sugars/pharmacology ; Humans ; Influenza A Virus, H1N1 Subtype/drug effects ; Influenza A Virus, H1N1 Subtype/physiology ; Influenza A Virus, H5N2 Subtype/drug effects ; Influenza A Virus, H5N2 Subtype/physiology ; Influenza, Human/drug therapy ; Influenza, Human/virology ; Uridine/chemistry ; Uridine/pharmacology
    Chemical Substances Antiviral Agents ; Deoxy Sugars ; Uridine (WHI7HQ7H85)
    Language English
    Publishing date 2013-10
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 306628-9
    ISSN 1872-9096 ; 0166-3542
    ISSN (online) 1872-9096
    ISSN 0166-3542
    DOI 10.1016/j.antiviral.2013.07.014
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Ocena realizacji pomiedzy proliferacja określana faza s cyklu komórkowego a apoptoza, po przeprowadzonej wtepnej chemoterapii w miesakach kościopochodnych u dzieci i młodiezy.

    Rytwiński, Krzysztof / Wnuk, Aleksander / Woźniak, Wojciech / Rychłowska, Magdalena / Bieńkowska, Małgorzata

    Medycyna wieku rozwojowego

    2004  Volume 8, Issue 4 Pt 2, Page(s) 1029–1036

    Abstract: Estimation of the S-phase of the cell cycle is applied to indicate the rate of cancer cells proliferation. This information is clinically useful, especially with the context of apoptosis (programmed cell death) stimulated by anticancer agents. The ... ...

    Title translation Assessment of the correlation between proliferation defined by S-phase cell cycle and apoptosis after preoperative chemotherapy in osteosarcomas of children and adolescents.
    Abstract Estimation of the S-phase of the cell cycle is applied to indicate the rate of cancer cells proliferation. This information is clinically useful, especially with the context of apoptosis (programmed cell death) stimulated by anticancer agents. The presented studies concerned above problems in children and adolescents osteosarcomas after preoperative chemotherapy. Flow cytometric method was used to analysis of S-phase cell cycle, aneuploidy and apoptosis (DNA histograms). The studies have shown that higher apoptotic index (percentage of apoptotic cells in "pre-G1/G0" position of DNA histograms), correlated with lower S-phase cell cycle and lower aneuploid fraction. It suggests that used chemotherapy treatment (Cisplatin, Adriamycin) induce apoptosis during S-phase cell cycle. Preliminary data are potentially important to predict clinical outcome after starting chemotherapy. This suggestion should be confirmed by estimation of other markers (early and late) of apoptosis.
    MeSH term(s) Adolescent ; Aneuploidy ; Antineoplastic Agents/therapeutic use ; Apoptosis/drug effects ; Bone Neoplasms/drug therapy ; Bone Neoplasms/pathology ; Bone Neoplasms/surgery ; Cell Proliferation/drug effects ; Chemotherapy, Adjuvant ; Child ; Female ; Flow Cytometry ; Humans ; Male ; Osteosarcoma/drug therapy ; Osteosarcoma/pathology ; Osteosarcoma/surgery ; S Phase/drug effects ; Treatment Outcome
    Chemical Substances Antineoplastic Agents
    Language Polish
    Publishing date 2004-10
    Publishing country Poland
    Document type English Abstract ; Journal Article ; Research Support, Non-U.S. Gov't
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top